Drugs - Lessons for clinical trials from natalizumab in multiple sclerosis

被引：21

作者：

Chaudhuri, A ^{[1
]}

机构：

[1] Oldchurch Hosp, Essex Ctr Neurol Sci, Romford RM7 0BE, Essex, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2006年 / 332卷 / 7538期

关键词：

D O I：

10.1136/bmj.332.7538.416

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the Food and Drug Administration for commercial licensing.

引用

页码：416 / 419

页数：4

共 19 条

[1] Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences [J].

Berger, JR ;

Koralnik, IJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :414-416

[2]

BJURSTEN M, 2005, EUR J IMMUNOL, V2274, P35

[3] Multiple sclerosis: looking beyond autoimmunity [J].

Chaudhuri, A ;

Behan, PO .

JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (07) :303-306

[4] Treatment of multiple sclerosis: beyond the NICE guidelines [J].

Chaudhuri, A ;

Behan, PO .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2005, 98 (05) :373-378

[5] Interferon beta, progressive MS, and brain atrophy [J].

Chaudhuri, A .

LANCET NEUROLOGY, 2005, 4 (04) :208-209

[6]

Chaudhuri A, 2003, NEW ENGL J MED, V348, P1598

[7] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process [J].

Confavreux, C ;

Vukusic, S ;

Adeleine, P .

BRAIN, 2003, 126 :770-782

[8] Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis [J].

Eriksson, M ;

Andersen, O ;

Runmarker, B .

MULTIPLE SCLEROSIS JOURNAL, 2003, 9 (03) :260-274

[9]

KEINSCHIMDTDEMA.BK, 2005, NEW ENGL J MED, V353, P369

[10]

Kleinke JD, 1998, BRIT MED J, V317, P899

← 1 2 →